Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

Biophytis SA announced that it has filed for a pre-submission meeting request with the Food and Drug Administration to discuss filing for Emergency Use Authorization in the United States for Sarconeos in the treatment of severe forms of COVID-19.

Scroll to Top